tiprankstipranks
Trending News
More News >
Cue Biopharma Inc (CUE)
NASDAQ:CUE
US Market

Cue Biopharma (CUE) Stock Statistics & Valuation Metrics

Compare
606 Followers

Total Valuation

Cue Biopharma has a market cap or net worth of $52.76M. The enterprise value is $69.30M.
Market Cap$52.76M
Enterprise Value$69.30M

Share Statistics

Cue Biopharma has 75,349,884 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding75,349,884
Owned by Insiders0.26%
Owned by Institutions8.33%

Financial Efficiency

Cue Biopharma’s return on equity (ROE) is -2.32 and return on invested capital (ROIC) is -181.74%.
Return on Equity (ROE)-2.32
Return on Assets (ROA)-1.26
Return on Invested Capital (ROIC)-181.74%
Return on Capital Employed (ROCE)-2.24
Revenue Per Employee226.51K
Profits Per Employee-992.05K
Employee Count41
Asset Turnover0.29
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Cue Biopharma is -1.51. Cue Biopharma’s PEG ratio is -0.39.
PE Ratio-1.51
PS Ratio0.00
PB Ratio1.55
Price to Fair Value3.51
Price to FCF-2.42
Price to Operating Cash Flow-2.43
PEG Ratio-0.39

Income Statement

In the last 12 months, Cue Biopharma had revenue of 9.29M and earned -40.67M in profits. Earnings per share was -0.72.
Revenue9.29M
Gross Profit9.29M
Operating Income-41.50M
Pretax Income-40.67M
Net Income-40.67M
EBITDA-37.53M
Earnings Per Share (EPS)-0.72

Cash Flow

In the last 12 months, operating cash flow was -34.72M and capital expenditures -161.00K, giving a free cash flow of -34.88M billion.
Operating Cash Flow-34.72M
Free Cash Flow-34.88M
Free Cash Flow per Share-0.46

Dividends & Yields

Cue Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.70
52-Week Price Change-17.89%
50-Day Moving Average0.70
200-Day Moving Average1.04
Relative Strength Index (RSI)61.12
Average Volume (3m)240.12K

Important Dates

Cue Biopharma upcoming earnings date is Sep 8, 2025, TBA (Confirmed).
Last Earnings DateMay 12, 2025
Next Earnings DateSep 8, 2025
Ex-Dividend Date

Financial Position

Cue Biopharma as a current ratio of 1.84, with Debt / Equity ratio of 29.41%
Current Ratio1.84
Quick Ratio1.84
Debt to Market Cap0.09
Net Debt to EBITDA0.33
Interest Coverage Ratio-52.14

Taxes

In the past 12 months, Cue Biopharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Cue Biopharma EV to EBITDA ratio is -1.15, with an EV/FCF ratio of -1.31.
EV to Sales5.15
EV to EBITDA-1.15
EV to Free Cash Flow-1.31
EV to Operating Cash Flow-1.32

Balance Sheet

Cue Biopharma has $13.14M in cash and marketable securities with $7.13M in debt, giving a net cash position of -$6.01M billion.
Cash & Marketable Securities$13.14M
Total Debt$7.13M
Net Cash-$6.01M
Net Cash Per Share-$0.08
Tangible Book Value Per Share$0.31

Margins

Gross margin is -45.04%, with operating margin of -446.86%, and net profit margin of -437.97%.
Gross Margin-45.04%
Operating Margin-446.86%
Pretax Margin-437.97%
Net Profit Margin-437.97%
EBITDA Margin-446.86%
EBIT Margin-446.54%

Analyst Forecast

The average price target for Cue Biopharma is $1.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$1.25
Price Target Upside60.26% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast13.83%
EPS Growth Forecast37.66%

Scores

Smart Score5
AI Score50.5
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis